<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784549</url>
  </required_header>
  <id_info>
    <org_study_id>CONTEST TRIAL RF-2009-1530324</org_study_id>
    <secondary_id>2011-005267-24</secondary_id>
    <nct_id>NCT01784549</nct_id>
  </id_info>
  <brief_title>Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease</brief_title>
  <acronym>CONTEST</acronym>
  <official_title>A Multi-center Phase II Randomized Study of Customized Neoadjuvant Therapy Versus Standard Chemotherapy in Non-small Cell Lung Cancer (NSLC) Patients With Resectable Stage IIIA (N2) Disease (CONTEST-TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Sanitaria Locale di Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera S. Maria della Misericordia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Tumori Giovanni Paolo II, BARI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, Napoli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Santa Maria Degli Angeli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Camillo Forlanini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Sanitaria Locale n.2 Savonese</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASL TO4, Chivasso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera &quot;Sant'Andrea&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera, Ospedale Civile di Legnano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The investigators hypothesized that NSCL patients receiving therapy based on their&#xD;
           baseline tumor markers levels would attain higher response rates than patients in the&#xD;
           control arm receiving non customized therapy.&#xD;
&#xD;
        -  patients with stage IIIA(N2) NSCLC will be randomized in a 2:1 ratio to customized&#xD;
           therapy based on biomarkers status (ERCC1, RRM1, TS and EGFR mutation) vs standard&#xD;
           chemotherapy.&#xD;
&#xD;
        -  The primary objective of this multicenter trial is to compare pathological complete&#xD;
           response of all subjects randomized, by treatment arm.&#xD;
&#xD;
        -  Secondary objectives are to compare all randomized subjects by treatment arm for:&#xD;
           response rate, disease-free survival, overall survival, one, two and three year survival&#xD;
           and safety profile.&#xD;
&#xD;
      The study is expected to demonstrate both the feasibility of this approach and the logistic&#xD;
      problems associated with a biomarker-driven therapeutic strategy in NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Subjects will be stratified by histology and biological markers (ERCC1, RRM1, TS, EGFR&#xD;
      mutation). Randomization will be centralized at the coordinating centre site. Patients will&#xD;
      receive chemotherapy with cisplatin + docetaxel or customized therapy for 3 cycles (60 days&#xD;
      with gefitinib) before surgery.&#xD;
&#xD;
      Every 4 months for 3 years and then every 6 months for 2 years following surgery, subjects&#xD;
      will be assessed by the investigator for adverse events related to study drug, documentation&#xD;
      of post study therapies received, DFS, and survival.&#xD;
&#xD;
      - Periodic evaluations of the trial data will be conducted by an independent data monitoring&#xD;
      committee to ensure subject safety and the validity and scientific merit of the study.&#xD;
&#xD;
      Assuming that the study is not stopped at the planned futility analyses or for safety&#xD;
      reasons, the final analysis will take place after the targeted number of events (pathological&#xD;
      complete response) is reached, which is estimated to take place 24 months post study&#xD;
      initiation.&#xD;
&#xD;
      - The pathological complete response (pCR)in the two groups will be computed in the ITT&#xD;
      populations and compared by means of the chi-square test without continuity correction. For&#xD;
      exploratory purposes, a multivariate logistic regression model will be fitted to the data,&#xD;
      with the pCR as the response variable and treatment (standard/ experimental) and&#xD;
      histo/molecular subgroup as covariate. The heterogeneity of the relative efficacy of the&#xD;
      tailored approach in the various subgroups (=subgroup analysis) will be evaluated by&#xD;
      including in the model the appropriate set of treatment-by-subgroup interaction terms, using&#xD;
      the standard likelihood ratio test. Time-to-event analyses (DFS and OS) will use standard&#xD;
      Kaplan-Meier estimators (with the Log-rank test) and semi-parametric PH regression models.&#xD;
      Safety will be summarized based on adverse events, vital signs and laboratory assessments. A&#xD;
      group sequential design is used to compare the Overall Survival in the two study arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 1, 2, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>at 1, 2, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>at 1, 2, and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib Pemetrexed Vinorelbine Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib day for 8 wks;&#xD;
Pemetrexed day 1 q 21 days for 3 cycles;&#xD;
Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;&#xD;
Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;&#xD;
Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;&#xD;
Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine</intervention_name>
    <arm_group_label>Cisplatin Docetaxel</arm_group_label>
    <arm_group_label>Gefitinib Pemetrexed Vinorelbine Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of a signed and dated written informed consent document prior to any study&#xD;
             specific procedures.&#xD;
&#xD;
          -  Age ≥18 years, male or female.&#xD;
&#xD;
          -  Histologically confirmed NSCLC.&#xD;
&#xD;
          -  Specimen tumor tissue obtained from mediastinoscopy&#xD;
&#xD;
          -  ECOG Performance status (PS) 0-1.&#xD;
&#xD;
          -  Stage IIIA(N2) patients with technical operable disease limited to T1a,b, T2a,b N2 M0;&#xD;
             T3 (&gt;7 cm) N2 M0.&#xD;
&#xD;
          -  Medically fit for resection by lobectomy or pneumonectomy.&#xD;
&#xD;
          -  Radiologically measurable disease (RECIST v1.1 criteria).&#xD;
&#xD;
          -  Prior surgery for NSCLC if resected ≥5 years.&#xD;
&#xD;
          -  No prior chemotherapy, targeted-therapy, investigational therapy or radiation for&#xD;
             NSCLC.&#xD;
&#xD;
          -  No uncontrolled medical problems.&#xD;
&#xD;
          -  No superior vena cava syndrome.&#xD;
&#xD;
          -  Peripheral neuropathy must be ≤ grade 1.&#xD;
&#xD;
          -  Acceptable hematologic and chemistry parameters.&#xD;
&#xD;
          -  Creatinine clearance &gt;50 ml/min.&#xD;
&#xD;
          -  Female patients or their partners must be surgically sterile or be postmenopausal, or&#xD;
             agree to use effective contraception while in trial treatment and for 3 months&#xD;
             thereafter.&#xD;
&#xD;
          -  Female patients with reproductive potential must have a negative pregnancy test (serum&#xD;
             or urine) within 72 hours prior to starting treatment.&#xD;
&#xD;
          -  Patients who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures including patient reported measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of mixed histology including elements of small cell or carcinoid lung&#xD;
             cancer.&#xD;
&#xD;
          -  Stage IIIA patients limited to T3 N1 M0; T3 (invasion) N2 M0; T4 N0, N1 M0.&#xD;
&#xD;
          -  Any clinically significant GI abnormalities, which may impair intake, transit or&#xD;
             absorption of gefitinib, such as the inability to take oral medication.&#xD;
&#xD;
          -  Current enrollment in another therapeutic clinical trial.&#xD;
&#xD;
          -  Any psychiatric or cognitive disorder that would limit the understanding or rendering&#xD;
             of informed consent and/or compromise compliance with the requirements of this study.&#xD;
&#xD;
          -  Past medical history of interstitial lung disease, drug-induced interstitial disease,&#xD;
             radiation pneumonitis which required steroid treatment or any evidence of clinically&#xD;
             active interstitial lung disease&#xD;
&#xD;
          -  Pre-existing idiopathic pulmonary fibrosis evidence by computerized tomography (CT)&#xD;
             scan at baseline.&#xD;
&#xD;
          -  Uncontrolled or significant CV disease, including: myocardial infarction within 12&#xD;
             months; uncontrolled angina within 6 months; congestive heart failure within 6 months;&#xD;
             diagnosed or suspected congenital long QT syndrome;&#xD;
&#xD;
          -  Any history of clinically significant ventricular arrhythmias (such as ventricular&#xD;
             tachycardia, ventricular fibrillation, or Torsades de pointes);&#xD;
&#xD;
          -  Prolonged QTc interval on pre entry ECG.&#xD;
&#xD;
          -  Any history of second or third degree heart block (may be eligible if currently have a&#xD;
             pacemaker);&#xD;
&#xD;
          -  Heart rate &lt;50/minute on baseline ECG;&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Evidence of prior malignancy (other than non melanoma skin cancer or in situ cervical&#xD;
             cancer, or localized and presumed cured prostate cancer with PSA &lt; ULN) within the&#xD;
             last 3 years.&#xD;
&#xD;
          -  Other severe acute or chronic medical condition that may increase the risk associated&#xD;
             with trial participation or may interfere with the interpretation of trial results&#xD;
             and, in the judgment of the investigator.&#xD;
&#xD;
          -  Patients in whom corticosteroid premedication was contraindicated.&#xD;
&#xD;
          -  HIV-positive patients on active treatment.&#xD;
&#xD;
          -  Medications are prohibited at baseline and prior to randomization if they affect the&#xD;
             pharmacokinetics of gefitinib, cisplatin, docetaxel, gemcitabine, vinorelbine and&#xD;
             pemetrexed or if they are mainly metabolized by CYP3A4.&#xD;
&#xD;
          -  Patients who are otherwise eligible can be enrolled only if drug substitution is&#xD;
             performed with acceptable clinical outcome prior to enrollment: known severe&#xD;
             hypersensitivity to gefitinib or other chemotherapeutic agents or any of the&#xD;
             excipients of the products.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Grossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Grossi, MD</last_name>
    <phone>+393355255484</phone>
    <email>fg1965@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Grossi, MD</last_name>
      <phone>+393355255484</phone>
      <email>fg1965@libero.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>February 2, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <last_update_submitted>November 23, 2014</last_update_submitted>
  <last_update_submitted_qc>November 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Francesco Grossi</investigator_full_name>
    <investigator_title>Chief, Lung Cancer Unit</investigator_title>
  </responsible_party>
  <keyword>NSCL</keyword>
  <keyword>biomarkers</keyword>
  <keyword>Customized Neoadjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

